Renal Denervation for Uncontrolled Hypertension: A Measurement-First, Program-Based Approach
Journal of Clinical Medicine · 31.03.2026 · 15 (7) · 2648
DOI: 10.3390/jcm15072648 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 31.03.2026. Verfasst von Lukasz Szarpak und 9 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Medical Sciences, Collegium Medicum, The John Paul II Catholic University of Lublin, 20-708 Lublin, Poland. Die Arbeit nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Objectives: Renal denervation (RDN) has re-emerged as an adjunctive treatment option for patients with uncontrolled or resistant hypertension, with contemporary sham-controlled trials showing a modest but reproducible reduction in out-of-office blood pressure. However, in routine practice, apparent treatment resistance often reflects pseudoresistance caused by the white-coat effect, poor measurement quality, therapeutic inertia, or nonadherence. This review aimed to summarize the contemporary evidence on renal denervation in uncontrolled or resistant hypertension and to propose a pragmatic, measurement-first framework for patient selection, integration into routine care, and a structured post-procedural response assessment.
Methods
This article is a narrative, implementation-focused review. A structured search of PubMed, Embase, Cochrane CENTRAL, and Web of Science was performed from database inception through January 2026. We prioritized the randomized sham-controlled RDN trials, major meta-analyses, guidelines, consensus documents, and studies addressing ABPM, HBPM, medication adherence, and telemonitoring.
Results
The contemporary sham-controlled trials support RDN as an adjunctive option with a modest blood pressure-lowering effect, which is best assessed by out-of-office measurements. The placebo-adjusted reductions in ambulatory systolic blood pressure were generally in the 4–6 mmHg range. Appropriate use requires the confirmation of sustained uncontrolled hypertension, the exclusion of pseudoresistance, the optimization of treatment, and an adherence assessment. We identified three phenotypes most likely to benefit and proposed a three-axis framework for a response assessment at 3 and 6 months.
Conclusions
RDN should be viewed not as a substitute for antihypertensive therapy but as a program-based adjunct for carefully selected patients. The measurement-first care pathway presented here should be interpreted as a pragmatic clinical model intended to operationalize the available trial and guideline evidence in routine care, rather than as a prospectively validated algorithm or formal consensus recommendation.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Institute of Medical Sciences, Collegium Medicum, The John Paul II Catholic University of Lublin, 20-708 Lublin, Poland.
- Henry JN Taub Department of Emergency Medicine, Baylor College of Medicine, Houston, TX 77030, USA.
- Department of Emergency Medicine, Ministry of Health Ankara Etlik City Hospital, Ankara 06170, Türkiye.
- 1st Department of Cardiology, Medical University of Gdansk, 80-214 Gdansk, Poland.
- Institute of Biological Sciences, Collegium Medicum, The John Paul II Catholic University of Lublin, 20-708 Lublin, Poland.
- Ludwik Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, 85-094 Bydgoszcz, Poland.
ORCID-Profile: Lukasz Szarpak, Milosz J Jaguszewski, Jacek Kubica, Maciej Maslyk, Michal Pruc, Karol Momot
Zitieren
APA
Szarpak, L., Katipoglu, B., Jaguszewski, M. J., Baier, A., Kubica, J., Maslyk, M., Pruc, M., Momot, K., Cander, B., & Lin, Q. (2026). Renal Denervation for Uncontrolled Hypertension: A Measurement-First, Program-Based Approach. Journal of Clinical Medicine, 15(7), 2648. https://doi.org/10.3390/jcm15072648
Vancouver
Szarpak L, Katipoglu B, Jaguszewski MJ, Baier A, Kubica J, Maslyk M, et al. Renal Denervation for Uncontrolled Hypertension: A Measurement-First, Program-Based Approach. Journal of Clinical Medicine. 2026;15(7):2648. doi:10.3390/jcm15072648
BibTeX
@article{Szarpak2026,
author = {Szarpak, Lukasz and Katipoglu, Burak and Jaguszewski, Milosz J and Baier, Andrea and Kubica, Jacek and Maslyk, Maciej and Pruc, Michal and Momot, Karol and Cander, Basar and Lin, Queran},
title = {Renal Denervation for Uncontrolled Hypertension: A Measurement-First, Program-Based Approach},
journal = {Journal of Clinical Medicine},
year = {2026},
volume = {15},
number = {7},
pages = {2648},
doi = {10.3390/jcm15072648}
}
EUVIMED